Contract research group Recipharm has leased AstraZeneca Biotech Laboratory (ABL) in Sodertalje, Sweden, bolting on recombinant protein and monoclonal antibody development capabilities to its offering.
The US authorities are turning up the heat on Icelandic generic drugmaker Actavis over manufacturing problems at the New Jersey plant which makes its recalled Digitek brand of the cardiac drug digoxin.
Alpharma moved a step closer to bringing its morphine product Embeda to market after a US Food and Drug Administration advisory panel agreed that it is less susceptible to abuse than other opioid analgesic products.
Cost cutting has sustained pharma profits in the faltering global economy, however top executives are starting to realise that reducing R&D capacity may not have been the smartest move in an era of weak pipelines and impending patent expiry, according...
Robert Sexauer, CEO of biopharmaceuticals group RCP Therapeutics, says the R&D investment deal signed with FirstPoint Biotech shows the attractiveness of the firm’s nano-medical pipeline, particularly given the current economic climate.
American Association of Pharmaceutical Scientist's (AAPS) president Dr Karen Habucky sets out the programme for the group's forthcoming annual meeting and exposition, which is being held in Atlanta, US between November 16- 20.